BTIG Research Reiterates Buy Rating for Harrow (NASDAQ:HROW)

Harrow (NASDAQ:HROW)‘s stock had its “buy” rating reiterated by BTIG Research in a research report issued on Wednesday, MarketBeat.com reports. They presently have a $63.00 target price on the stock. BTIG Research’s target price would suggest a potential upside of 83.09% from the stock’s previous close.

HROW has been the topic of a number of other reports. William Blair reiterated an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Cantor Fitzgerald lowered their price objective on shares of Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. HC Wainwright lifted their price objective on shares of Harrow from $69.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. Finally, Zacks Research lowered shares of Harrow from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 3rd. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Harrow has an average rating of “Moderate Buy” and an average price target of $71.14.

Harrow Price Performance

HROW opened at $34.41 on Wednesday. The stock’s 50-day moving average price is $44.80 and its 200 day moving average price is $43.49. Harrow has a 12-month low of $20.85 and a 12-month high of $54.85. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -202.40 and a beta of 0.05. The company has a current ratio of 2.20, a quick ratio of 2.06 and a debt-to-equity ratio of 4.67.

Hedge Funds Weigh In On Harrow

Several large investors have recently bought and sold shares of the business. Penn Capital Management Company LLC purchased a new stake in Harrow during the third quarter worth approximately $15,717,000. Luxor Capital Group LP purchased a new position in Harrow in the third quarter valued at approximately $14,807,000. New York State Common Retirement Fund increased its stake in Harrow by 1,944.7% in the third quarter. New York State Common Retirement Fund now owns 213,789 shares of the company’s stock valued at $10,300,000 after purchasing an additional 203,333 shares during the last quarter. Diametric Capital LP acquired a new stake in Harrow during the second quarter worth approximately $4,748,000. Finally, Bank of America Corp DE raised its holdings in Harrow by 266.8% during the second quarter. Bank of America Corp DE now owns 213,448 shares of the company’s stock worth $6,519,000 after purchasing an additional 155,258 shares in the last quarter. Hedge funds and other institutional investors own 72.76% of the company’s stock.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.